Cytarabine conjugates with biologically active molecules and their potential anticancer activity

Neoplasma

Volumn 56, Issue 3, 2009, Pages 177-186

  Novotny, L ^a   Rauko, P ^b  

^a KUWAIT UNIVERSITY   (Kuwait)

^b INSTITUTE OF CHEMISTRY   (Slovakia)

Author keywords

Anticancer activity; Arabinosylcytosine; Biologic activity; Conjugates; Cytarabine

Indexed keywords

5' (11 DEOXYCORTICOSTERONE 21 PHOSPYRYL) 1 BETA DEXTRO ARABINOFURANOSYLCYTOSINE; 5' (6ALPHA METHYLPREDNISOLONE 21 PHOSPYRYL) 1 BETA DEXTRO ARABINOFURANOSYLCYTOSINE; 5' (CORTEXOLONE 21 PHOSPYRYL) 1 BETA DEXTRO ARABINOFURANOSYLCYTOSINE; 5' (CORTICOSTERONE 21 PHOSPYRYL) 1 BETA DEXTRO ARABINOFURANOSYLCYTOSINE; 5' (DEXAMETHASONE 21 PHOSPYRYL) 1 BETA DEXTRO ARABINOFURANOSYLCYTOSINE; 5' (FLUDROCORTISONE 21 PHOSPYRYL) 1 BETA DEXTRO ARABINOFURANOSYLCYTOSINE; ACLARUBICIN; ANTINEOPLASTIC AGENT; BETA DEXTRO GLUCAN CYTARABINE; CYCLOCYTIDINE (2,2' ANHYDRO CYTARABINE); CYTARABINE; CYTARABINE 5' DIPHOSPHATE RAC 1 OCTADECYL 2 O PALMITOYL 1 THIOGLYCEROL; CYTARABINE DERIVATIVE; CYTARABINE FLUORODEOXYURIDINE CONJUGATE; ENOCITABINE; N 4 (ACYLPEPTIDYL)CYTARABINE CONJUGATE; N 4 STEAROLY 1 BETA DEXTRO ARABINOFURANOSYLCYTOSINE; PEPTIDE T CYTARABINE CONJUGATE; POLY GLUTAMIC ACID CYTARABINE CONJUGATE; POLY N 5 (2 HYDROXYETHYL)GLUTAMINE CYTARABINE CONJUGATE; POLYGALACTURONIC ACID CYTARABINE CONJUGATE; PREDNISOLONE; STEROID CYTARABINE CONJUGATE; SULFANILAMIDE CYTARABINE CONJUGATE; UNCLASSIFIED DRUG; VALYL CYTARABINE CONJUGATE; DRUG DERIVATIVE;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; BIOLOGICAL ACTIVITY; CANCER INHIBITION; CANCER THERAPY; CELL CYCLE ARREST; CYTOTOXICITY; DRUG CONJUGATION; DRUG METABOLISM; DRUG STABILITY; DRUG STRUCTURE; HEMATOLOGIC MALIGNANCY; HUMAN; LEUKEMIA; LIPOPHILICITY; MITOSIS INHIBITION; NONHUMAN; PHOSPHORYLATION; SHORT SURVEY; ANIMAL; CHEMISTRY; REVIEW; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CYTARABINE; HUMANS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 67650312034     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: 10.4149/neo_2009_03_177     Document Type: Short Survey

References (58)

1. GALMARINI CM, Jordheim L, Dumontet C. Pyrimidine nucleoside analogs in cancer treatment. Expert Rev Anticancer Ther 2003; 3: 717-728. doi:10.1586/14737140.3.5.717 (Pubitemid 37337110)
2. Galmarini CM, Mackey JR, Dumontet C. Nucleoside analogues and nucleobases in cancer treatment. Lancet Oncol. 2002; 3: 415-424. doi:10.1016/S14702045(02) 00788X (Pubitemid 36958272)
3. Garcia-Carbonero R, Ryan DP, Chabner BA. Cytidine analogs. In: Cancer Chemotherapy and Biotherapy: Principles and Practice, 3rd Edition (Eds. Chabner BA and Longo DL). Lippincott Williams & Wilkins, Philadelphia, 2001, p. 265-294.
4. DIPIRO JT, TALBERT RL, YEE GC, MATZKE GR et al. Cancer treatment and chemotherapy. In: Pharmacotherapy: A Pathophysiologic Approach (Eds. Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG and Posey LM). McGraw-Hill Companies, New York, 2002, p. 2175-2222.
5. RANG HP, DALE MM, RITTER JM et al. Cancer Chemotherapy. In: Pharmacology (Eds. Rang HP, Dale MM, Ritter JM and Moore PK). Churchill Livingstone, Philadelphia, 2002, p. 693-710.
6. RUSSO D, MALAGOLA M, DE VIVO A et al. Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, AraC and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukemia patients. Br J Haematol 2005; 131: 172-179. doi:10.1111/j.13652141. 2005.05745.x
7. WEISS MA. Treatment of adult patients with relapsed or refractory acute lymphoblastic leukemia (ALL). Leukemia 1997;11 Suppl 4: S28-30.
8. WANG WS, TZENG CH, CHIOU TJ et al. High-dose cytarabine and mitoxantrone as salvage therapy for refractory non-Hodgkin's lymphoma. Jpn J Clin Oncol 1997; 27: 154-157. doi:10.1093/jjco/27.3.154 (Pubitemid 127516323)
9. Yamauchi T, Kawai Y, Goto N et al. Close correlation of 1-beta-D-arabinofuranosylcytosine 5′-triphosphate, an intracellular active metabolite, to the therapeutic efficacy of N(4)-behenoyl-1-beta-D- arabinofuranosylcytosine therapy for acute myelogenous leukemia. Jpn J Cancer Res. 2001; 92: 975-982.
10. Aoshima M, Tsukagoshi S, Sakurai Y et al. Antitumor activities of newly synthesized N4-acyl-1-beta-D-arabinofuranosyl-cytosine. Cancer Res 1976; 36: 2726-2732.
11. Yamada K, Kawashima K, Kato Y et al. Pharmacologic and clinical studies of N4-behenoyl-1-beta-D-arabinofuranosylcytosine. Recent Results Cancer Res 1980; 70: 219-229.
12. Kataoka T, Sakurai Y. Effect and mode of action of N4-behenoyl-beta-D- arabinofuranosylcytosine. Recent Results Cancer Res 1980; 70: 147-151.
13. Novotny L, Reichelova V, Balazova E et al. The biotransformation and cytotoxic activity of arabinosylcytosine 5′-chloro-5′-deoxy analog. Anti-Cancer Drugs 1991; 2: 495-502.
14. Peters GJ, Braakhuis BJ, de Bruijn EA et al. Enhanced therapeutic efficacy of 5′deoxy-5-fluorouridine in 5-fluorouracil resistant head and neck tumours in relation to 5-fluorouracil metabolizing enzymes. Br J Cancer 1989; 59: 327-334.
15. Novotny L, Farghali H, Ryba M, et al. Structure-intestinal transport and structure-metabolism correlations of some potential cancerostatic pyrimidine nucleosides in isolated rat jejunum. Cancer Chemother Pharmacol. 1984; 13: 195-199. doi:10.1007/BF00269028 (Pubitemid 14048990)
16. Farghali H, Novotny L, Ryba M, et al. Kinetics of transport and metabolism of 1-β-D-arabinofuranosylcytosine and structural analogs by everted perfused rat jejunum. Biochem Pharmacol. 1983; 33: 655-662. doi:10.1016/00062952(84)903228 (Pubitemid 14159323)
17. 17] Braess J, Wegendt C, Feuring-Buske M et al. Leukaemic blasts differ from normal bone marrow mononuclear cells and CD34+ haemopoietic stem cells in their metabolism of cytosine arabinoside. Br J Haematol. 1999; 105: 388-393. doi:10.1111/j.13652141.1999.01338.x (Pubitemid 29232159)
18. Aoshima M, Tsukagoshi S, Sakurai Y et al. Atitumor activities of newly synthesized N4-acyl-1-beta-D-arabinofuranosylcytosine. Cancer Res. 1976; 36: 2726-2732.
19. Kataoka T, Sakurai Y. Effect and mode of action of N4-behenoyl-beta-D- arabinofuranosylcytosine. Recent Results Cancer Res. 1980; 70: 147-151.
20. Aoshima M, Tsukagoshi S, Sakurai Y et al. N4 Behenoyl-1-beta-D- arabinofuranosylcytosine as a potential new antitumor agent. Cancer Res. 1977; 37: 2481-2486.
21. Yamada K, Kawashima K, Kato Y et al. Pharmacologic and clinical studies of N4-behenoyl-1-beta-D-arabinofuranosylcytosine. Recent Results Cancer Res. 1980; 70: 219-229.
22. Higashigawa M, Ochiai H, Ohkubo T et al. Incorporation of N4-behenoyl-1-beta-D-arabinofuranosylcytosine into DNA as 1-beta-D- arabinofuranosylcytosine. Med Oncol Tumor Pharmacother 1988; 5: 265-271.
23. Maehara Y, Kusumoto T, Kusumoto H et al. In vitro sensitivity of various human tumors to 1-beta-D-arabinofuranosylcytosine and N4-behenoyl-1-beta-D- arabinofuranosylcytosine. Chemotherapy 1989; 35: 181-186.
24. Yamauchi T, Kawai Y, Goto N, et al. Close correlation of 1-beta-D-arabinofuranosylcytosine 5′-triphosphate, an intracellular active metabolite, to the therapeutic efficacy of N(4)-behenoyl-1-beta-D- arabinofuranosylcytosine therapy for acute myelogenous leukemia. Jpn J Cancer Res 2001; 92: 975-982.
25. Bergman AM, Kuiper CM, Voorn DA, et al. Antiproliferative activity and mechanism of action of fatty acid derivatives of arabinofuranosylcytosine in leukemia and solid tumor cell lines. Biochem Pharmacol 2004; 67: 503-511. doi:10.1016/j.bcp.2003.09.028 (Pubitemid 38232890)
26. Dobashi N, Asai O, Yano S et al. Aclarubicin plus behenoyl cytarabine and prednisolone for previously treated acute myeloid leukemia patients. Leuk Lymphoma 2006; 47: 2203-2207. doi:10.1080/10428190600756490 (Pubitemid 44650099)
27. Choe YH, Conover CD, Wu D et al. Anticancer drug delivery systems: N4-acyl poly(ethyleneglycol) prodrugs of araC. I. Efficacy in solid tumors. J Control Release 2002; 79: 41-53. doi:10.1016/S01683659(01)004692
28. Cheon EP, Hong JH, Han HK. Enhanced cellular uptake of AraC via a peptidomimetic prodrug, L-valyl-ara-C in Caco-2 cells. J Pharm Pharmacol 2006; 58: 927-932. doi:10.1211/jpp.58.7.0007
29. Menger FM, Guo Y, Lee AS. Synthesis of a lipid/peptide/drug conjugate: N4-(acylpeptidyl)-ara-C. Bioconjug Chem 1994;5: 162-166. doi:10.1021/bc00026a601
30. Manfredini S, Marastoni-M, Tomatis R et al. Peptide T-araC conjugates: solid-phase synthesis and biological activity of N4-(acylpeptidyl)-araC. Bioorg Med Chem 2000; 8: 539-547. doi:10.1016/S09680896(99)00317X (Pubitemid 30122360)
31. Pert CB, Hill JM, Ruff MR et al. Octapeptides deduced from the neuropeptide receptor-like pattern of antigen T4 in brain potently inhibit human immunodeficiency virus receptor binding and T-cell infectivity. Proc Natl Acad Sci USA 83 (1986), p. 9254. doi:10.1073/pnas.83.23.9254
32. Kato Y, Saito M, Fukushima H et al. Antitumor activity of 1- -D-arabinofuranosylcytosine conjugated with polyglutamic acid and its derivative. Cancer Res 1984; 44: 25-30. (Pubitemid 14178055)
33. Kery V, Novotny L, Tihlarik K, et al. Preparation, properties and antileukemic activity of arabinosylcytosine polysaccharide conjugates. Int J Biochem 1990; 22: 1203-1207. doi:10.1016/0020711X(90)90122J (Pubitemid 20353317)
34. Novotny L, Balazova E, Sandula J et al Treatment of leukemia L1210 and P388 by arabinosylcytosine-polysaccharide conjugates. Int J Cancer 1991; 47: 281-284. doi:10.1002/ijc.2910470218
35. Venditti JM, Baratta MC, Greenberg NH et al. Studies of the L1210 antileukemic activity of O-2,2′-cyclocytidine, monoacetate (anhydro-ara-C; NSC-129220)-comparison with cytosine arabinoside (NSC63878) with respect to treatment schedule dependency. Cancer Chemother Rep 1972; 56: 483-492.
36. Hoshi A, Kanazawa F, Kuretani K. et al 2,2′-O-cyclocytidine, an antitumor cytidine analog resistant to cytidine deaminase. Gann 1971; 62: 145-146.
37. Novotny L, Reichelova V, Balazova E. et al. Comparison of some biochemical parameters of arabinosylcytosine and cyclocytidine in L1210 murine leukemia cells. Neoplasma 1990; 37: 13-22. (Pubitemid 20146692)
38. Novotny L, Hrebabecky H, Beranek J. Synthesis of the sulfonamido derivatives of arabinonucleosides. Collect Czech Chem Commun 1985; 50: 383-392.
39. Mohan R, Banerjee M, Ray A et al. Antimitotic sulfonamides inhibit microtubule assembly dynamics and cancer cell proliferation. Biochemistry 2006; 45: 5440-5449. doi:10.1021/bi0523409 (Pubitemid 43673175)
40. Supuran CT. Indisulam: an anticancer sulfonamide in clinical development. Expert Opin Investig Drugs 2003; 12: 283-287. doi:10.1517/13543784.12.2.283
41. Zhang GS, Liu DS, Dai CW et al. Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib. Am J Hematol 2006; 81: 242-255. doi:10.1002/ajh.20542
42. Chow LW, Loo WT, Wai CC et al. Study of COX-2, Ki67, and p53 expression to predict effectiveness of 5-fluorouracil, epirubicin and cyclophosphamide with celecoxib treatment in breast cancer patients. Biomed Pharmacother 2005; 59: S298-301. doi:10.1016/S07533322(05)800502
43. Pastorekova S, Parkkila S, Pastorek J et al. Carbonic anhydrases: current state of the art, therapeutic applications and future prospects. J Enzyme Inhib Med Chem 2004; 19: 199-229. doi:10.1080/14756360410001689540 (Pubitemid 39004275)
44. Scozzafava A, Owa T, Mastrolorenzo A et al. Anticancer and antiviral sulfonamides. Curr Med Chem 2003; 10: 925-953. doi:10.2174/0929867033457647
45. Novotny L, Phillips OA, Rauko P et al. Antileukemic activity of sulfonamide conjugates of arabinosylcytosine. Exp Oncol 2006; 28: 293-298. (Pubitemid 46226100)
46. Krizmanic I, Visnjevac A, Luic M et al. Synthesis, structure, and biological evaluation of C-2 sulfonamido pyrimidine nucleosides. Tetrahedron 2003; 59: 4047-4057. doi:10.1016/S0040-4020(03)00589-1 (Pubitemid 36589055)
47. Hong CI, An SH, Nechaev A et al. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugates of optical isomers of ether and thioether lipids. Lipids 1993; 28: 1021-1026. doi:10.1007/BF02537125
48. Hong CI, Kirisits AJ, Nechaev A et al. Nucleoside conjugates. 11. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine and cytidine conjugates of thioether lipids. J Med Chem 1990; 33: 1380-1386. doi:10.1021/jm00167a016
49. Hong CI, Bernacki RJ, Hui SW. et al. Formulation, stability, and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugate of thioether phospholipid. Cancer Res 1990; 50: 4401-4406.
50. Alexander RL, Morris-Natschke SL, Ishaq KS et al. Synthesis and cytotoxic activity of two novel 1-dodecylthio-2-decyloxypropyl-3-phosphatidic acid conjugates with gemcitabine and cytosine arabinoside Med Chem 2003; 46: 4205-4208. doi:10.1021/jm020571x
51. Alexander RL, Greene BT, Torti SV et al. A novel phospholipid gemcitabine conjugate is able to bypass three drug-resistance mechanisms. Cancer Chemother Pharmacol 2005; 56: 15-21. doi:10.1007/s00280-004-0949-0
52. Strasser S, Maier S, Leisser C et al. 5-FdUrd-araC heterodinucleoside re-establishes sensitivity in 5-FdUrd- and AraC-resistant MCF-7 breast cancer cells overexpressing ErbB2. Differentiation 2006; 74: 488-498. doi:10.1111/j.14320436.2006.00082.x (Pubitemid 44922494)
53. Horber DH, Cattaneo-Pangrazzi RM, von Ballmoos P et al. Cytotoxicity, cell-cycle perturbations and apoptosis in human tumor cells by lipophilic N4-alkyl-1-beta-D-arabinofuranosylcytosine derivatives and the new heteronucleoside phosphate dimer arabinocytidylyl-(5′→5′)-N4- octadecyl-1-beta-D-arabinofuranosylcytosine. J Cancer Res Clin Oncol 2000; 126: 311-319. doi:10.1007/s004320050349
54. Maier S, Strasser S, Saiko P, et al. Analysis of mechanisms contributing to AraC-mediated chemoresistance and re-establishment of drug sensitivity by the novel heterodinucleoside phosphate 5-FdUrd-araC. Apoptosis 2006; 11: 427-440. doi:10.1007/s10495-006-4066-x
55. Rauko P, Novotny L, Mego M, et al. In vitro and in vivo antileukemic effect of novel dimers consisting of 5-fluorodeoxyuridine and arabinofuranosylcytosine. Neoplasma 2007; 54: 68-74.
56. Hong CI, Nechaev A, West CR. Nucleoside conjugates as potential antitumor agents. 2. Synthesis and biological activity of 1-(beta-D-arabinofuranosyl) cytosine conjugates of prednisolone and prednisone. J Med Chem 1979; 22: 1428-1432. doi:10.1021/jm00197a030
57. Hong CI, Nechaev A, Kirisits AJ. et al. 1-beta-D-arabinofuranosylcytosine conjugates of corticosteroids as potential antitumor agents. Eur J Cancer Clin Oncol 1983 19:1105-1112. doi:10.1016/0277-5379(83)90035-4
58. Hong CI, Nechaev A, Kirisits AJ. et al. Nuleosideconjugates as potential antitumor agents. 3. Synthesis and antitumor activity of 1-(beta-D- arabinofuranosyl)cytosine conjugates of corticosteroids. J Med Chem 1980; 23: 1343-1347. doi:10.1021/jm00186a011